Validation of the Stockholm3 Test for Detection of Prostate Cancer in the Swiss Population

Validation of the Prostate Cancer Biomarker Stockholm3 for Improved Disease Detection and Classification in the Swiss Population

The purpose of this study is to collect blood samples to investigate the prognostic performance of the STHLM3 test in a population of Swiss and German men suspected of harbouring prostate cancer based on a combination of elevated PSA levels (e.g. >2.5 ng/ml) and/or pathological digital rectal examination and/or MRI-findings.

Inclusion Criteria:

• Planned prostate biopsy due to suspicion of prostate cancer (usually due to a combination of elevated PSA levels [e.g. >2.5 ng/ml] and/or pathological digital rectal examination and/or MRI-findings)
• Written informed consent by the participant

Exclusion Criteria:

• Severe anemia (Hb <60g/l)
• Previously already established diagnosis of prostate cancer.